PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.51 -0.02 (-3.40%)
As of: Aug 20, 2026 · 3:59 PM EDT

PharmaCyte Biotech (PMCB) Revenue (2010 - 2012)

PharmaCyte Biotech (PMCB) posted quarterly Revenue of $6287.0 for Q4 2012, down 68.32% year-over-year from $19844.0 in Q4 2011, and down 5.12% quarter-over-quarter from $6626.0 in Q3 2012.

PharmaCyte Biotech (PMCB) Revenue (2010 - 2012) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Revenue for 3 consecutive years, with $6287.0 the latest figure, recorded in Q4 2012.

  • In Q4 2012, Revenue fell 68.32% year-over-year to $6287.0; the TTM figure through Jul 2013 stood at $6287.0 (down 88.23% YoY), while the FY2013 annual figure was $12160.0, down 81.73% from the prior year.
  • Revenue eased to $6287.0 in Q4 2012 per PMCB's latest filing, from $6626.0 in the prior quarter.
  • Across five years, Revenue topped out at $51146.0 in Q2 2011 and bottomed at $6287.0 in Q4 2012.
  • Historically, Revenue has averaged $20546.8 across 3 years, with a median of $19803.0 in 2011.
  • Annual changes were most pronounced in 2011 — Revenue grew 25.05% — and 2012, when it plunged 86.94%.
  • PharmaCyte Biotech's Revenue stood at $15869.0 in 2010, then increased by 25.05% to $19844.0 in 2011, then plunged by 68.32% to $6287.0 in 2012.
  • Business Quant data shows PMCB's Revenue at $6287.0 in Q4 2012, $6626.0 in Q3 2012, and $6681.0 in Q2 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 3.33 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 4.29 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn 1.52 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn 145.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 1.71 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 1.29 Bn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn 425.49 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - 674.14 Mn
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 1.06 Bn
10 PharmaCyte Biotech 4.30 Mn 4.30 Mn - -

Historic Data

Download Data
DateValue
Oct 31, 2012 6,287.00
Jul 31, 2012 6,626.00
Apr 30, 2012 6,681.00
Jan 31, 2012 20,271.00
Oct 31, 2011 19,844.00
Jul 31, 2011 19,762.00
Apr 30, 2011 51,146.00
Jan 31, 2011 32,022.00
Oct 31, 2010 15,869.00
Jul 31, 2010 26,960.00